How Soon Will Iluvien be Available to Treat Diabetic Macular Edema?
September 5, 2010
I recently wrote an extensive article about Illuvien and the future of ophthalmic drug delivery systems.
Illuvien is a new hope in the treatment of diabetic macular edema (DME). Illuvien delivers fluocinolone acetonide (FA), a corticosteroid, to the retina for up to three years, thus forgoing the need for multiple drug injections and/or laser treatments to alleviate the symptoms.
Well, Alimera, the company behind Illuvien, received good news yesterday in the form of notification from the FDA that its NDA (new drug application) for Iluvien had been accepted for filing and granted Priority Review status. FDA Priority Review status is granted to therapies that offer major advances in treatment or provide a treatment where no adequate therapy exists. This status accelerates the standard review time from 10 months to six months.
With priority review, Alimera could receive a response from the FDA in the fourth quarter regarding its NDA for Iluvien, which was submitted at the end of June 2010.
This is exciting news for patients, and will provide an alternative to laser, frequent injections and off-label treatments currently available for DME.
Here is a link to the full article.
You might also enjoy...
- FDA Delays Approval of Iluvien to Treat Diabetic Macular Edema
- Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for Wet Age-Related Macular Degeneration
- Alimera Sciences Announces Study of Iluvien® in Patients With Macular Edema Due to Retinal Vein Occlusion
- New Website Helps Patients Evaluate Stem Cell Treatment Options
- pSivida Announces Positive Results From The Two Phase 3 FAME™ Trials of Iluvien in Patients With Diabetic Macular Edema
Jump down to form below to submit your own comments